Felzartamab联合来那度胺-地塞米松对比来那度胺-地塞米松治疗复发或难治性多发性骨髓瘤:一项开放标签、平行对照、随机3期试验
在中国41家医院开展的开放标签、平行对照、随机3期试验,纳入295例复发或难治性多发性骨髓瘤患者,按2:1随机分配至Felzartamab联合来那度胺-地塞米松组或来那度胺-地塞米松组。
要点
- 联合组3-4级不良事件以中性粒细胞减少(55%)、淋巴细胞减少(41%)等血液学毒性更常见。
- 联合组治疗相关死亡6%,对照组2%,最常见严重不良事件为肺炎(22% vs 10%)。
核心结论
- Felzartamab联合来那度胺-地塞米松较来那度胺-地塞米松单用显著延长复发或难治性多发性骨髓瘤患者的无进展生存期。
- 该联合方案有望成为中国复发或难治性多发性骨髓瘤患者的新治疗选择。
研究设计与样本
- 在中国41家医院开展的开放标签、平行对照、随机3期试验。
- 纳入295例既往至少接受过一线系统治疗且对来那度胺不敏感的复发或难治性多发性骨髓瘤成人患者,按2:1随机分配。
- 随机分层因素包括国际分期体系分期、既往治疗线数和既往来那度胺暴露情况。
- 主要终点为独立评审委员会评估的无进展生存期,在全分析集(至少接受一剂研究治疗的患者)中评估。
主要发现
- 最常见的3-4级不良事件:中性粒细胞减少(联合组55% vs 对照组23%)、淋巴细胞减少(41% vs 15%)、白细胞减少(39% vs 11%)、血小板减少(26% vs 11%)、肺炎(23% vs 13%)、贫血(17% vs 20%)、低钾血症(16% vs 10%)、上呼吸道感染(8% vs 2%)。
- 最常见的严重不良事件为肺炎(联合组22% vs 对照组10%)。
- 治疗相关死亡:联合组6%(11/192),对照组2%(2/97)。
临床怎么用
- 对于既往至少一线治疗且对来那度胺不敏感的复发或难治性多发性骨髓瘤患者,可考虑Felzartamab联合来那度胺-地塞米松方案。
- 治疗期间需密切监测血液学毒性及感染(尤其肺炎),及时处理不良事件。
局限性
- 本研究仅纳入中国患者,全部为亚洲人种,结果外推至其他人群需谨慎。
- 开放标签设计可能引入偏倚。
- 对照组仅接受来那度胺-地塞米松,非当前所有标准方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Complement-dependent cytotoxicity (CDC) of CD38 monoclonal antibodies has been associated with infusion-related reactions and might contribute to reduced clinical efficacy of CDC-reliant CD38 antibodies, particularly in patients with relapsed or refractory multiple myeloma with 1q21+. We aimed to evaluate felzartamab, a novel anti-CD38 monoclonal antibody that retains potent antibody-dependent cellular cytotoxicity and antibody-dependent cellular phagocytosis while exhibiting markedly attenuated CDC activity in Chinese patients with relapsed or refractory multiple myeloma. METHODS: In this open-label, parallel-controlled, randomised, phase 3 trial conducted at 41 hospitals in China, adults aged 18 years or older with relapsed or refractory multiple myeloma who had received at least one previous line of systemic therapy, and were not refractory to lenalidomide were enrolled. Patients were randomly assigned (2:1) through a central interactive web response system, stratified by International Staging System stage, number of previous lines of therapy, and previous lenalidomide exposure, to receive intravenous felzartamab (16 mg/kg on days 1 and 4 during week 1, weekly week 2-12, every 2 weeks week 13-24, and every 4 weeks thereafter) plus once daily lenalidomide (25 mg orally on days 1-21 of each 28-day cycle) and once weekly oral dexamethasone (40 mg for patients aged ≤75 years and 20 mg for those >75 years) or lenalidomide and dexamethasone alone. The primary endpoint was progression-free survival, defined as the time from randomisation to disease progression or death from any cause, whichever occurred first, assessed by an independent review committee in the full analysis set (all randomly assigned patients who received at least one dose of study treatment). Safety was assessed in all patients who received at least one dose of study treatment. This trial is registered with ClinicalTrials.gov (NCT03952091) and is closed to enrolment. FINDINGS: Between March 27, 2019, and Oct 20, 2021, 390 patients were assessed for eligibility, 295 of whom were enrolled and randomly assigned to felzartamab plus lenalidomide-dexamethasone (n=195) or lenalidomide-dexamethasone (n=100). The full analysis set included 289 patients (191 in the felzartamab plus lenalidomide-dexamethasone group and 98 in the lenalidomide-dexamethasone group). 185 (64%) of 289 patients were male, 104 (36%) were female, and all were of Asian ethnicity. At a median follow-up of 34·5 months (IQR 16·8-40·2) in the felzartamab plus lenalidomide-dexamethasone group and 28·7 months (10·8-38·8) in the lenalidomide-dexamethasone group, median progression-free survival was 18·9 months (95% CI 13·6-24·0) with felzartamab plus lenalidomide-dexamethasone versus 10·4 months (5·8-13·9) with lenalidomide-dexamethasone (hazard ratio 0·62 [95% CI 0·45-0·86]; p=0·0035). The most common grade 3-4 adverse events were neutropenia (105 [55%] of 192 vs 22 [23%] of 97), lymphopenia (79 [41%] vs 15 [15%]), leukopenia (74 [39%] vs 11 [11%]), thrombocytopenia (49 [26%] vs 11 [11%]), pneumonia (44 [23%] vs 13 [13%]), anaemia (33 [17%] vs 19 [20%]), hypokalaemia (30 [16%] vs ten [10%]), and upper respiratory tract infection (15 [8%] vs two [2%]). The most common serious adverse event was pneumonia (42 [22%] vs ten [10%]). Treatment-related deaths occurred in 11 (6%) of 192 patients in the felzartamab plus lenalidomide-dexamethasone group (five of unknown cause [possibly related to treatment], two due to pneumonia, one due to febrile infection, one due to cardiac arrest, one due to cerebral infarction, and one due to pneumonitis) and two (2%) of 97 patients in the lenalidomide-dexamethasone group (one due to pneumonia and one due to a fall]). INTERPRETATION: Felzartamab plus lenalidomide-dexamethasone significantly prolonged progression-free survival compared with lenalidomide-dexamethasone alone, supporting felzartamab plus lenalidomide-dexamethasone as a potential new treatment option for Chinese patients with relapsed or refractory multiple myeloma. FUNDING: TJ Biopharma.
引用
- He H, Shang J, Wang Y, et al. Felzartamab plus lenalidomide-dexamethasone versus lenalidomide-dexamethasone for relapsed or refractory multiple myeloma: an open-label, parallel-controlled, randomised, phase 3 trial. Lancet Haematol. 2026. PMID: 42822478. doi:10.1016/S2352-3026(26)00223-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。